Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. The Company's lead candidate, AMA0076, targets glaucoma, a condition which damages the optic nerve resulting in vision loss and ultimately blindness.

Amakem's product pipeline is based on its unique 'Localized Drug Action' platform which generates novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.